Keyphrases
Pharmacokinetics
61%
Flavopiridol
54%
Chronic Lymphocytic Leukemia
48%
Lenalidomide
38%
Relapsed or Refractory Acute Myeloid Leukemia
37%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
30%
Phase I Study
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Relapsed or Refractory
20%
AR-42
19%
Maximum Tolerated Dose
18%
Melphalan
18%
Acute Myeloid Leukemia
17%
Histone Deacetylase Inhibitor (HDACi)
17%
In Cancer
17%
Extracellular Vesicles
16%
OSU-2S
16%
Tumor
15%
Phase II Study
15%
High Risk
15%
Pharmacokinetic Study
15%
Multiple Myeloma Patients
15%
Dose Escalation
14%
Clinical Pharmacology
14%
High Dose
14%
Dosing Schedule
13%
Mass Spectrometry Methods
13%
Decitabine
13%
Phase 1 Study
13%
FTY720
13%
Riboflavin
12%
Phase I Trial
12%
Tumor Lysis Syndrome
11%
Tolerability
11%
Dose-limiting Toxicity
11%
Partial Response
11%
Progression-free Survival
11%
Leukemia Patients
11%
Multiple Myeloma
11%
Overall Survival
11%
Human Plasma
10%
Neutropenia
10%
Targeted Delivery
10%
Dose Level
10%
Pharmacokinetic Data
10%
Independent Regulation
9%
Clinical Response
9%
Clinical Outcomes
9%
Stable Disease
9%
High-dose Melphalan
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Flavopiridol
51%
Chronic Lymphatic Leukemia
48%
Lenalidomide
32%
Malignant Neoplasm
30%
Neoplasm
27%
Multiple Myeloma
25%
Disease
24%
Acute Myeloid Leukemia
23%
Pharmacodynamics
21%
Melphalan
19%
P-Glycoprotein
16%
Solid Malignant Neoplasm
14%
Progression Free Survival
14%
Histone Deacetylase Inhibitor
14%
Maximum Tolerated Dose
14%
Bioavailability
13%
Chemotherapy
13%
Decitabine
13%
Fingolimod
13%
microRNA
13%
Phase I Trials
12%
Cytotoxicity
12%
Tumor Lysis Syndrome
11%
Liposome
10%
Neutropenia
10%
Elimination
9%
Anticarcinogen
9%
Immunogenicity
9%
Acute Leukemia
9%
Receptor
9%
Clinical Trial
9%
Effusion
8%
Adverse Event
8%
Tolerability
8%
Hematologic Malignancy
8%
Electrospray Ionization
8%
Overall Survival
8%
Tubulin
7%
IC50
7%
Paclitaxel
7%
Pharmacotherapy
7%
Drug Absorption
7%
Biological Marker
7%
Tumor Suppressor Protein
7%
Small Interfering RNA
7%
Liver Cell Carcinoma
7%
Cyclin Dependent Kinase Inhibitor
7%
Pharmacokinetic Parameter
7%
Myeloma
7%